Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair...Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like

Pfizer Inc., of New York, said top-line results from a Phase III study showed Lyrica (pregabalin) capsules CV were as effective as levetiracetam (Keppra, UCB SA) as adjunctive therapy for refractory partial onset seizures in adults with epilepsy

Teva Pharmaceutical Industries Ltd., of Jerusalem, said top-line results of its Phase III program testing narcolepsy drug Nuvigil (armodafinil) as adjunct therapy in adults with major depression associated with bipolar I disorder showed that the drug produced a numerical improvement but did not reach statistical significance in meeting its primary endpoint – determining whether armodafinil treatment, at a dosage of 150 mg per day, is more effective than placebo as adjunct therapy to mood

Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, said top-line results showed that all four Phase III studies of empagliflozin, a sodium glucose co-transporter-2 inhibitor, in Type II diabetes met their primary endpoints, defined as significant changes in HbA1c from baseline compared to placebo, with the 10-mg and 25-mg doses

Pfizer Inc., of New York, said top-line data from a Phase III study testing pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicated that the product had a statistically significant positive effect compared to placebo in the primary endpoint, defined as time to loss of therapeutic response

Pfizer Inc., of New York, said top-line results from a Phase III study testing the 165-mg dose and the 330-mg dose of pregabalin controlled-release (CR) formulation in adults with partial onset seizures showed that the trial did not meet its primary endpoint comparing the change in seizure frequency to placebo, although both doses were well tolerated

Pfizer Inc., of New York, disclosed top-line Phase III data from an open-label long-term safety study of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, noncancer pain

Pfizer Inc., of New York, reported top-line results from the Phase III ORAL Start study of JAK inhibitor tofacitinib in moderate to severe active rheumatoid arthritis (RA

Pfizer Inc., of New York, reported top-line data showing that Lyrica (pregabalin) resulted in low discontinuation symptoms after tapering treatment following three months and six months in generalized anxiety disorder patients...In separate news, Pfizer reported top-line data showing that Lyrica does not affect the reproductive function in healthy males when compared to placebo

Teva Pharmaceutical Industries Ltd., of Jerusalem, reported top-line data from the Phase III GALA (Glatiramer Acetate Low-Frequency Administration) trial testing 40 mg/1 ml glatiramer acetate (GA 40 mg/1 ml) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis patients

Ltd., of Osaka, Japan, reported top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal Phase III trial

Forest Laboratories Inc., of New York, and Pierre Fabre Medicament, of Castres, France, reported top-line results in a Phase III trial showing that levomilnacipran significantly reduced depression symptoms in patients with major depressive disorder compared to placebo, as early as week one and at each subsequent visit, as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated

Forest Laboratories Inc., of New York, reported top-line results from two Phase III trials of cariprazine (RGH-188) in acute exacerbation of schizophrenia, showing that patients treated with the dopamine D3-preferring D3/D2 receptor partial agonist experienced significant symptom improvement compared to the placebo group, as measured by the Positive And Negative Syndrome Scale, the primary endpoint in both studies

Ltd., of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including tumor necrosis factor-alpha antagonists

Inc., of Whitehouse Station, N.J., reported top-line results from the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar, showing the drug, an oral protease activated receptor 1 thrombin receptor angonist, met the primary endpoint in preventing clot formation and reducing cardiovascular events